Holen Sie sich die Stockscreener-App
0.91
2.39%
0.0212
Handel nachbörslich:
.88
-0.03
-3.30%
Schlusskurs vom Vortag:
$0.8888
Offen:
$0.871
24-Stunden-Volumen:
115.84K
Relative Volume:
0.77
Marktkapitalisierung:
$23.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.22M
KGV:
-0.5129
EPS:
-1.7742
Netto-Cashflow:
$-17.31M
1W Leistung:
-8.03%
1M Leistung:
-14.15%
6M Leistung:
+7.06%
1J Leistung:
+95.28%
1-Tages-Spanne:
$0.8634
$0.9577
1-Wochen-Bereich:
$0.8634
$1.20
52-Wochen-Spanne:
$0.375
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
Firmenname
AEON Biopharma Inc.
Sektor
Branche
Telefon
(949) 354-6499
Adresse
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.91 | 22.49M | 0 | -39.22M | -17.31M | -1.7742 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-18 | Eingeleitet | H.C. Wainwright | Buy |
AEON Biopharma Inc. Aktie (AEON) Neueste Nachrichten
AEON Biopharma Receives NYSE American Non-Compliance Notice Due to Stockholders’ Equity Deficit and Ongoing Listing Challenges - Minichart
AEON Biopharma Receives Second NYSE American Notice for Listing Non-Compliance - geneonline.com
AEON Biopharma, Inc. (AEON) stock price, news, quote and history - Yahoo Finance Australia
AEON Biopharma receives additional NYSE American non-compliance notice - MSN
AEON (AEON) CFO awarded 754,717 restricted stock units vesting over four years - stocktitan.net
AEON Biopharma (AEON) CFO John Bencich files initial insider ownership report - stocktitan.net
AEON Biopharma Receives Additional NYSE American Noncompliance Notice - TipRanks
AEON Biopharma Faces Listing Compliance Risk - Intellectia AI
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards - The Manila Times
AEON Biopharma Received Notice of Noncompliance - TradingView
New AEON finance chief gets stock awards tied to NYSE compliance - stocktitan.net
AEON Biopharma (NYSE American: AEON) faces added NYSE equity noncompliance risk - stocktitan.net
AEON stays on NYSE despite $55 million deficit as deadline nears - stocktitan.net
AEON Forecast, Price Target & Analyst Ratings | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma 2025 Financial Review - AlphaStreet
Stock Market Recap: Whats the profit margin of AEON Biopharma Inc - baoquankhu1.vn
AEON Biopharma reports biosimilar progress, secures financing By Investing.com - Investing.com Australia
Can AEON Biopharma Inc keep up with sector leaders2026 Price Swings & AI Powered Market Entry Strategies - baoquankhu1.vn
AEON Biopharma 2025 10-K: Net loss $39.2M, EPS $(3.95) - TradingView
AEON Biopharma (AEON) advances Botox biosimilar plan but warns on going concern - stocktitan.net
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
[8-K] AEON Biopharma, Inc. Reports Material Event - stocktitan.net
AEON Biopharma reports biosimilar progress, secures financing - investing.com
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program - The Manila Times
AEON's Botox biosimilar matched 3,400 amino acids as FDA mapped next steps - stocktitan.net
Latest AEON NewsAEON Biopharma Presents Positive Results fr... - Stock Titan
Biotech Landscape Update: Regulatory Approvals and Mergers - Intellectia AI
Aeon Biopharma announces FDA feedback after Type 2a meeting - Yahoo Finance
AEON Biopharma receives FDA feedback on botulinum toxin biosimilar - Investing.com
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program - The Manila Times
FDA maps next steps for AEON's bid to bring a Botox biosimilar - Stock Titan
AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Wednesday - Defense World
If You Invested $1,000 in Aeon Biopharma (AEON) - stocktitan.net
AEON Biopharma, Inc.: Fundamental Analysis and Financial Ratings | AEON | US00775E1029 - marketscreener.com
Technical Analysis: Whats the profit margin of AEON Biopharma Inc2026 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Travel Stocks: How much upside does AEON Biopharma Inc haveQuarterly Trade Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Profit Recap: Can AEON Biopharma Inc stock outperform in a bear marketMarket Performance Report & Low Risk Entry Point Guides - baoquankhu1.vn
Risk Analysis: Is AEON Biopharma Inc stock good for income investors2026 Trade Ideas & Safe Entry Point Identification - baoquankhu1.vn
AEON Technical Analysis | Trend, Signals & Chart Patterns | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma (NASDAQ: AEON) CMO granted RSUs and modifies 1,316,872-unit award - Stock Titan
AEON Biopharma names John Bencich as chief financial officer - Investing.com Australia
AEON Biopharma Appoints John Bencich as Chief Financial Officer - The Manila Times
AEON Biopharma Strengthens Finance Leadership with New CFO - TipRanks
AEON Biopharma names John Bencich as chief financial officer By Investing.com - Investing.com Canada
AEON appoints John Bencich as CFO; Jennifer Sy employment terms confirmed - TradingView
New AEON Biopharma (NYSE: AEON) CFO hired as company expands inducement equity pool - Stock Titan
AEON Biopharma, Inc. Appoints John Bencich as Chief Financial Officer, Effective as of March 9, 2026 - marketscreener.com
How cyclical is AEON Biopharma Inc. Class stock compared to rivalsInflation Watch & AI Enhanced Trading Signals - Naître et grandir
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting - The Manila Times
AEON (AEON) CLO adds large stock awards and converts prior RSUs - Stock Titan
Finanzdaten der AEON Biopharma Inc.-Aktie (AEON)
Umsatz
Nettogewinn
Free Cashflow
ENV
AEON Biopharma Inc.-Aktie (AEON) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FISCHER JOST | Director |
May 20 '25 |
Buy |
0.51 |
60,000 |
30,360 |
206,785 |
| FISCHER JOST | Director |
May 19 '25 |
Buy |
0.50 |
50,000 |
24,940 |
146,785 |
0.87%
0.11%
Kapitalisierung:
|
Volumen (24h):